Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01594918 · ClinicalTrials.gov registry record · Phase 1
Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer
A Phase 1 study, sponsored by Rahul Aggarwal.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT01594918 is a Phase 1 study that has completed, run by Rahul Aggarwal. The registered enrollment target is 25 participants.
The verdict
NCT01594918, a Phase 1 study, has completed, sponsored by Rahul Aggarwal.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of cabazitaxel, mitoxantrone, and prednisone (CAMP) in combination at different dose levels and to determine the highest dose that does not cause bad side effects. The investigators want to find out what effects, good and/or bad, CAMP has on patients and their metastatic castration-resistant prostate cancer.
Interventions
- DRUG Prednisone
- DRUG Mitoxantrone
- DRUG Cabazitaxel
- DRUG Pegfilgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-06 |
| Est. Completion | 2017-06-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01594918
The ClinicalTrials.gov registry entry for NCT01594918 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rahul Aggarwal, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Prednisone is the first listed.
NCT01594918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01594918 about?
NCT01594918 is a clinical study titled "Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer". The purpose of this study is to test the safety of cabazitaxel, mitoxantrone, and prednisone (CAMP) in combination at different dose levels and to determine the highest dose that does not cause bad side effects. The investigators want to find out what effects, good and/or bad, CAMP has on patients a...
What is the current status of trial NCT01594918?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2012-06. Estimated completion is 2017-06-23.
What interventions are being tested in trial NCT01594918?
The interventions under investigation include: Prednisone (DRUG), Mitoxantrone (DRUG), Cabazitaxel (DRUG), Pegfilgrastim (DRUG).
Who is sponsoring clinical trial NCT01594918?
This trial is sponsored by Rahul Aggarwal, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.